AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today the global launch of Signature® LTx (Leukemia Translocation Panel), a multiplexed reverse transcription PCR (RT-PCR) assay that detects nine common leukemia-associated translocations. The assay is performed on a Luminex cytometer using a multi-probe liquid bead array method. The liquid bead array format provides comprehensive information in a single well, providing efficiency and cost benefits to the laboratory.
